Abstract

DALFAMPRIDINE; TREATMENT OF WALKING IMPAIRMENT IN MULTIPLE SCLEROSIS

Shraddha Autade*, R. B. Laware and G. S. Shinde

ABSTRACT

In Central Nervous System the multiple sclerosis is a potentially diabling disorder, in youngster this is incurable disorder.in this Physiopathology include: neurodegenerative and inflammatory demyelination. The inflaming demyelination of MS that is especially promoted by a massive activating of the immune system against putative CNS antigen(s) ends up in loss of myelin/oligodendrocyte complex that slows down or halts impulse conduction in denuded axons. The cause and curative for Multiple sclerosis remain undiscovered. A disease in which the immune system eats away at the protective covering of nerves. Dalfampridine is approved by FDA for treatment of MS. It is a potassium channel blocker which acts at the central and peripheral nervous systems, which increases conduction of in demyelinated axons and enhance walking ability of MS patients. The objective of this paper is to provide a survey of the pharmacology, pharmacokinetics, clinical trials, side effects and interactions of dalfampridine. It is used in treatment of MS patients. The clinical trials have been providing for the safety and efficacy of fampridine in MS patients with the degree of gait improvement as the main outcome.

Keywords: Dalfampridine, multiple sclerosis, gait, 4-AP.